Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

The advent of immune checkpoint inhibition (ICI) using antibodies against PD1 and its
ligand PDL1 has prompted substantial efforts to develop complementary drugs. Although …

Checkpoint immunotherapy holds great potential to treat malignancies via blocking the
immunosuppressive signaling pathways, which however suffers from inefficiency and off …

KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a
longtime goal. Recently, inhibitors were developed that bind KRASG12C-GDP and react …

The inhibitory receptor PD-1 suppresses T cell activation by recruiting the phosphatase SHP-
2. However, mice with a T-cell-specific deletion of SHP-2 do not have improved antitumor …

Protein phosphatases act as key regulators of multiple important cellular processes and are
attractive therapeutic targets for various diseases. Although extensive effort has been …

Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein
tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues …

SHP2 mediates the activities of multiple receptor tyrosine kinase signaling and its function in
endothelial processes has been explored extensively. However, genetic studies on the role …

Purpose: SHP2 inhibitors offer an appealing and novel approach to inhibit receptor tyrosine
kinase (RTK) signaling, which is the oncogenic driver in many tumors or is frequently …

Recently developed KRASG12C inhibitory drugs are beneficial to lung cancer patients
harboring KRASG12C mutations, but drug resistance frequently develops. Because of the …